Creative Planning Boosts Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Creative Planning grew its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 1.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,845 shares of the medical instruments supplier’s stock after purchasing an additional 659 shares during the period. Creative Planning owned approximately 0.06% of West Pharmaceutical Services worth $15,430,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Fidelis Capital Partners LLC purchased a new position in West Pharmaceutical Services during the first quarter worth about $27,000. Crewe Advisors LLC increased its position in shares of West Pharmaceutical Services by 322.7% in the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 71 shares during the last quarter. Quarry LP raised its stake in West Pharmaceutical Services by 155.3% in the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares in the last quarter. Hazlett Burt & Watson Inc. bought a new stake in West Pharmaceutical Services during the first quarter valued at approximately $40,000. Finally, Northwest Investment Counselors LLC purchased a new position in West Pharmaceutical Services in the 1st quarter worth approximately $40,000. Institutional investors own 93.90% of the company’s stock.

Insider Buying and Selling

In related news, VP Charles Witherspoon sold 1,029 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.53% of the stock is currently owned by corporate insiders.

West Pharmaceutical Services Stock Performance

West Pharmaceutical Services stock opened at $300.16 on Tuesday. West Pharmaceutical Services, Inc. has a fifty-two week low of $265.00 and a fifty-two week high of $413.70. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.68 and a current ratio of 2.34. The stock has a market cap of $21.77 billion, a P/E ratio of 39.60, a price-to-earnings-growth ratio of 11.09 and a beta of 1.01. The firm’s fifty day moving average price is $301.57 and its 200-day moving average price is $334.35.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). The firm had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The company’s revenue for the quarter was down 6.9% on a year-over-year basis. During the same period last year, the firm earned $2.11 EPS. On average, equities research analysts expect that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.